Back to search

Clemson University

Novel Fusion Protein IL-12/Fas<sub>TI</sub> for Cancer Immunogene Therapy

Abstract

dc:description.abstract

Cancer immunotherapies using cytokines demonstrated effective in previous studies, whereas one major obstacle with the strategy is the severe side effects when administrated systemically at high doses. Additionally, cancer cells’ escape from immune destruction has brought another challenge for cytokine therapy. Current approaches to cancer immunotherapy largely involve the immune factors designed to revive endogenous immune responsiveness, which renders high-efficient gene delivery system in urgent demand. In the first phase of our study, we demonstrated that fusion protein mIL-12/FasTI, encoded by cDNA of mouse interleukin-12 and transmembrane and intracellular domains of Fas, showed enhanced NK cell activity and anti-tumor cytotoxicity in vitro when expressed by stable tumor cell clones. As the second stage of study, a lentiviral vector-based gene delivery was used to deliver the fusion gene construct directly to tumor cells. Lentiviral vectors (pLenti7.3/IL-12/FasTI or Lent-IF) were constructed and used to transduce tumor cells. Preliminary data indicates that the constructs were efficiently delivered to tumor cells as assayed by RT-PCR and immunohistochemistry (IHC). The biological functions of the constructs as delivered by lentiviral system, such as NK cell activation, caspase-3 activity, Annexin-V apoptosis detection and tumor growth in vitro, have been demonstrated with statistical significance. This study represents a further step of bifunctional fusion protein cancer immunotherapy towards patient treatment.

Degree

thesis:*
Name thesis:degree_name
Doctor of Philosophy (PhD)
Level thesis:degree_level
Dissertation
Discipline thesis:degree_discipline
Biological Sciences

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Yang, Xi
Contributors dc:contributor
  • Dr. Yanzhang Wei, committee chair
  • Dr. Charlie Rice
  • Dr. Jeremy Tzeng
  • Dr. Xianzhong Yu

Subjects

dc:subject × 6

Identifiers

dc:identifier.*
Repository record dc:identifier
https://open.clemson.edu/all_dissertations/2092

Chain of custody

source
Harvested from
Clemson University
Base URL
open.clemson.edu/do/oai/
Last updated
2026-11-19
Source record
OAI-PMH GetRecord
citation

Yang, Xi. Novel Fusion Protein IL-12/Fas<sub>TI</sub> for Cancer Immunogene Therapy. Dissertation thesis, https://open.clemson.edu/all_dissertations/2092